Get the Stockscreener App
19.70
0.66%
-0.13
Capricor Therapeutics Inc stock is traded at $19.70, with a volume of 2.46M.
It is down -0.66% in the last 24 hours and down -33.24% over the past month.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
See More
Previous Close:
$19.83
Open:
$19.7731
24h Volume:
2.46M
Relative Volume:
1.90
Market Cap:
$1.14B
Revenue:
$11.13M
Net Income/Loss:
$-114.59M
P/E Ratio:
-8.5171
EPS:
-2.313
Net Cash Flow:
$-113.96M
1W Performance:
+1.34%
1M Performance:
-33.24%
6M Performance:
-15.09%
1Y Performance:
+204.01%
1-Day Range:
$18.30
$20.18
1-Week Range:
$18.30
$20.54
52-Week Range:
$4.30
$40.37
Capricor Therapeutics Inc Stock (CAPR) Company Profile
Name
Capricor Therapeutics Inc
Sector
Industry
Phone
(310) 358-3200
Address
10865 ROAD TO THE CURE, SAN DIEGO, CA
Compare CAPR vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CAPR
Capricor Therapeutics Inc
|
19.70 | 1.14B | 11.13M | -114.59M | -113.96M | -2.313 |
VRTX
Vertex Pharmaceuticals Inc
|
477.36 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
656.01 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
918.22 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.23 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
271.77 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-30-25 | Initiated | Alliance Global Partners | Buy |
| Jun-26-25 | Initiated | B. Riley Securities | Buy |
| May-20-25 | Initiated | Roth Capital | Buy |
| Oct-21-24 | Initiated | Piper Sandler | Overweight |
| May-17-24 | Initiated | Oppenheimer | Outperform |
| Jan-05-24 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-26-22 | Initiated | Ladenburg Thalmann | Buy |
| Dec-26-18 | Downgrade | Maxim Group | Buy → Hold |
| Jan-26-18 | Reiterated | H.C. Wainwright | Buy |
| Sep-15-17 | Reiterated | H.C. Wainwright | Buy |
| Feb-13-17 | Resumed | Rodman & Renshaw | Buy |
| Jul-06-16 | Resumed | H.C. Wainwright | Buy |
| Jun-15-16 | Initiated | ROTH Capital | Buy |
View All
Capricor Therapeutics Inc Stock (CAPR) Latest News
This Capricor Insider Sold 24,000 Shares Before the Drop. With a New Catalyst on the Way, Is It Time to Buy? - Yahoo Finance
This Capricor Insider Sold 24,000 Shares Before the Drop. With a New Catalyst on the Way, Is It Time to Buy? - The Motley Fool
CAPR|Capricor Therapeutics Inc|Price:19.700|Chg%:-0.130 - TradingKey
Capricor Therapeutics, Inc. Revenue Breakdown – NASDAQ:CAPR - TradingView
FDA Showdown Week: CAPR, NRXP, REPL And MRNA Face Make-Or-Break Regulatory Decisions - Yahoo Finance
Stock Traders Purchase Large Volume of Call Options on Capricor Therapeutics (NASDAQ:CAPR) - MarketBeat
Behavioral Patterns of CAPR and Institutional Flows - Stock Traders Daily
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
CAPR: Capricor Therapeutics Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
CAPR Stock On Track To Clock Weekly Gains Ahead Of Critical FDA Panel — Retail Deems It A ‘Binary Event’ - Stocktwits
Capricor Therapeutics (NASDAQ:CAPR) Shares Up 7.4%Here's What Happened - MarketBeat
Oppenheimer Maintains Capricor Therapeutics(CAPR.US) With Buy Rating, Maintains Target Price $54 - Moomoo
S&P 500, Dow, Nasdaq Futures Climb As Trump Says Iran Ceasefire Holds Despite Fresh Hormuz Tensions: IREN, CRWV, CAPR, TTD Stocks In Focus - Stocktwits
Walleye Capital LLC Acquires New Position in Capricor Therapeutics, Inc. $CAPR - MarketBeat
CAPR Stock Draws Investor Attention After AAN Presentation For DMD Therapy - Stocktwits
CAPR Stock Gains Steam: Former Capricor Exec Could Become FDA’s Top Gene Therapy Regulator Ahead Of High-Stakes DMD Decision - Stocktwits
CAPR Stock Eyes 1st Weekly Gain In 5 Weeks: Capricor’s DMD Therapy Faces FDA Panel Review Next Week, Retail Sees 'Excellent Opportunity' - Stocktwits
Capricor Therapeutics (NASDAQ:CAPR) Share Price Crosses Below Two Hundred Day Moving AverageHere's Why - MarketBeat
CAPR Stock Sinks After-Hours: Capricor Launches Legal Fight Over DMD Therapy Rollout Ahead Of FDA Review - Stocktwits
Capricor Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Krasney Karen - Moomoo
Investors in Capricor Therapeutics, Inc. Should Contact The Gros - GuruFocus
Can Capricor Therapeutics’ (CAPR) FDA-Linked HQ Expansion Reshape Its Risk Profile And Strategic Flexibility? - Sahm
CAPR Stock Surged 17% Today — What’s Fueling The Rally? - Stocktwits
Capricor Or Sarepta: Two DMD Stocks Enter A High-Stakes Week – Which One Has More Upside? - Stocktwits
ETFs Investing in Capricor Therapeutics, Inc. Stocks - TradingView
News | Capricor signs San Diego’s largest biotech lease of the year - CoStar
Capricor Therapeutics (CAPR) Signs Expansion Lease Tied To Deramiocel FDA Approval - Sahm
Cantor Fitzgerald reiterates Overweight on Capricor stock at $62 By Investing.com - Investing.com Canada
Capricor Therapeutics, Inc. Files Form 8-K: Company Details, Stock Information, and Key SEC Disclosures (July 2026) - Minichart
Capricor Therapeutics (NASDAQ: CAPR) signs 171,000 sq ft San Diego HQ lease - Stock Titan
Capricor Therapeutics (NASDAQ:CAPR) Shares Cross Below 200 Day Moving AverageTime to Sell? - MarketBeat
Michael T Maurer Net Worth (2026) - GuruFocus
Moderna, Takeda and Capricor on the verge of notching big drug approvals - Pharma Voice
CAPR Stock Slumps But Wall Street Reiterates Optimism For Deramiocel Approval - Stocktwits
Capricor Therapeutics Company Profile & Introduction - Moomoo
Price to earnings forward of Capricor Therapeutics, Inc. – NASDAQ:CAPR - TradingView
Capricor Therapeutics (CAPR) Gets a Buy from Cantor Fitzgerald - The Globe and Mail
Cantor Fitzgerald Maintains Capricor Therapeutics(CAPR.US) With Buy Rating, Maintains Target Price $62 - Moomoo
Cantor Fitzgerald reiterates Overweight on Capricor stock ahead of FDA decision - Investing.com Canada
Capricor Therapeutics (CAPR) Is Down 5.8% After FDA Adcom Set, Russell Exit NewsHas The Bull Case Changed? - Sahm
CAPR Stock Heads For Best Week In Nearly A Month: CEO Says 'No Way' Deramiocel Gets Only Conditional Approval - Stocktwits
Capricor falls as FDA sets up AdCom meeting to review Duchenne therapy - MSN
Capricor Therapeutics Inc Stock (CAPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Capricor Therapeutics Inc Stock (CAPR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Krasney Karen | EVP, GENERAL COUNSEL |
Jun 25 '26 |
Sale |
30.38 |
24,100 |
732,158 |
30,547 |
| Bergmann Anthony | CHIEF FINANCIAL OFFICER |
Jun 25 '26 |
Option Exercise |
3.18 |
24,100 |
76,638 |
35,323 |
| Bergmann Anthony | CHIEF FINANCIAL OFFICER |
Jun 25 '26 |
Sale |
30.38 |
24,100 |
732,158 |
11,223 |
| Krasney Karen | EVP, GENERAL COUNSEL |
Jun 22 '26 |
Option Exercise |
3.18 |
500 |
1,590 |
31,047 |
| Krasney Karen | EVP, GENERAL COUNSEL |
Jun 24 '26 |
Option Exercise |
3.18 |
400 |
1,272 |
30,947 |
| Krasney Karen | EVP, GENERAL COUNSEL |
Jun 22 '26 |
Sale |
30.00 |
500 |
15,000 |
30,547 |
| Krasney Karen | EVP, GENERAL COUNSEL |
Jun 24 '26 |
Sale |
30.00 |
400 |
12,000 |
30,547 |
| Bergmann Anthony | CHIEF FINANCIAL OFFICER |
Jun 22 '26 |
Option Exercise |
3.18 |
500 |
1,590 |
11,723 |
| Bergmann Anthony | CHIEF FINANCIAL OFFICER |
Jun 24 '26 |
Option Exercise |
3.18 |
400 |
1,272 |
11,623 |
| Bergmann Anthony | CHIEF FINANCIAL OFFICER |
Jun 22 '26 |
Sale |
30.00 |
500 |
15,000 |
11,223 |
0.46%
0.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):